Bounded definition
The cited study applies CHANGE-seq across many guides and compares nominations with cellular activity and genomic context. Within this page, that proposition is limited to The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity.
Definition and evidence boundary
An in-vitro circularized-genomic-DNA assay for high-throughput nomination of Cas9 cleavage activity. The bounded proposition retained by the canonical record is: The cited study applies CHANGE-seq across many guides and compares nominations with cellular activity and genomic context.
The applicable scope is The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity. This definition must not be generalized beyond the cited source and exact record boundary.
Claims: urn:maha:claim:change-seq-off-target-nomination
Mechanism and technical context
The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets. This is the source-bound technical context for the record; no uncited mechanism is added by the compiler.
In-vitro cleavage nomination does not directly measure editing frequency or consequence in the intended cell product or organism. The mechanism or method is therefore presented as one component of a larger system, not as evidence for every downstream outcome.
Claims: urn:maha:claim:change-seq-off-target-nomination
How to interpret the evidence
There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices. The evidence maturity recorded here is single study, and the claim kind is empirical claim.
This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded. In-vitro nomination is not identical to editing frequency or biological consequence in a treated cell population or organism. These qualifications travel with the claim whenever it is reused.
Claims: urn:maha:claim:change-seq-off-target-nomination
What the source supports and what remains unknown
The inspected source supports exactly this: The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets. It was read at Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295.
What remains unknown is everything outside that locator. In-vitro cleavage nomination does not directly measure editing frequency or consequence in the intended cell product or organism. No quantity, comparison, or downstream outcome is established here unless a separately scoped record measures it.
Claims: urn:maha:claim:change-seq-off-target-nomination
Source identity, locator, and reuse boundary
The bound source is “CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity” by Christopher R. Lazzarotto, Nhu T. Nguyen, J. A. Tangprasertchai, S. C. Malagon-Lopez, et al., published by Nature Biotechnology on 2020-06-22; its declared stable identity is doi:10.1038/s41587-020-0555-7.
The inspected-content locator is Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295. Reuse is limited to citation-with-paraphrase. Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced. This metadata establishes source identity and inspection scope, not the truth of claims outside the cited locator.
Claims: urn:maha:claim:change-seq-off-target-nomination
Comparison and calculation boundary
Applicability is decided explicitly, not filled with generic material.
This record carries 1 source-bound proposition and therefore has no second supported side. A comparison would have to be manufactured from an adjacent title rather than from a second inspected claim, which the gate forbids.
The canonical claim declares no reproducible numerical inputs, equation, units, or uncertainty propagation; recorded uncertainty kind is qualitative. Supplying sample values would invent an unsupported quantitative result.
Limitations and prohibited inference
The claim stops where its evidence stops.
- record boundary
In-vitro cleavage nomination does not directly measure editing frequency or consequence in the intended cell product or organism.
- record boundary
A source-bounded mechanism, method, or measurement record does not establish manufacturing yield, economic advantage, safety, clinical benefit, or commercial readiness unless those outcomes are measured in a separately scoped record.
- prohibited inference
Do not treat the change-seq off-target nomination record as medical advice, a treatment recommendation, or evidence of general clinical readiness.
- prohibited inference
Do not transfer a reported result across hardware, organisms, protocols, datasets, operating conditions, or outcome definitions without a declared comparison contract.
- editorial
This compilation reorganizes an existing inspected claim and its declared source; it does not add a new experiment, measurement, or independent replication.
- editorial
Internal editorial inspection is not external peer review, and no result on this page has been independently reproduced.
Related records and mathematical bridges
Typed links expose context without asserting equivalence.
Cell-line versus primary-cell evidence
Cites the same source as this record, so the two are related through the evidence rather than through wording.
Selection: shared source
In-vitro versus in-vivo evidence
Declared strategic-dependency edge into this record, so it is positioned earlier in the same bounded sequence.
Selection: bridge edge
Off-target nomination versus confirmation
Declared mechanistic-dependency edge from this record. The edge is navigational and asserts no equivalence or causation beyond the cited source scope.
Selection: bridge edge
When no declared bridge edge is present, related records are linked by shared evidence or canonical domain adjacency. Those links are navigational and do not claim mathematical or physical equivalence.
Connected domain graph
Typed dependencies preserve publication state.
Only independently canonical records receive public links and relation statements. Draft graph topology remains private.
Off-target nomination versus confirmation
outbound connection · comparison
CHANGE-seq nominations require cellular confirmation under matched editor and delivery conditions.
Off-target nomination versus confirmation
inbound connection · comparison
CHANGE-seq provides an in-vitro nomination channel.
In-vitro versus in-vivo evidence
inbound connection · comparison
In-vitro nomination supports but does not replace cellular and organism measurements.
Claim ledger
Every proposition keeps its own evidence state.
The cited study applies CHANGE-seq across many guides and compares nominations with cellular activity and genomic context.
- Scope
- The constructs, biological systems, protocols, assays, datasets, and comparisons reported in CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity.
- Boundary
- In-vitro cleavage nomination does not directly measure editing frequency or consequence in the intended cell product or organism.
- Uncertainty
- There is no universal effect estimate for this method; numerical results remain attached to the source experiment, biological system, assay, and analysis choices.
- Replication
- This candidate records one bounded source package. Independent replications and contradictory results must be compiled separately before evidence maturity is upgraded.
Primary sources
Citation, locator, rights, and boundary travel together.
Source 1 · Nature Biotechnology
CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity
Christopher R. Lazzarotto, Nhu T. Nguyen, J. A. Tangprasertchai, S. C. Malagon-Lopez, et al.
- Exact locator
- Abstract; Figures 1–6; Methods; datasets PRJNA625995 and GSE149295.
- Establishes
- The study develops an in-vitro circularized-DNA assay for Cas9 activity and compares nominations with cellular activity and genomic context for specified targets.
- Boundary
- In-vitro nomination is not identical to editing frequency or biological consequence in a treated cell population or organism.
- Rights basis
- citation with paraphrase · Maha paraphrases the source-level result and links to the version of record; no article passage is reproduced.
- Declared interests
- The article declares patent and company relationships involving genome-editing assays and therapeutics.